Production (Stage)
Palvella Therapeutics, Inc.
PVLA
$25.40
$1.918.13%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 8.97M | 5.94M | 4.84M | 3.42M | 2.93M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.21M | 14.10M | 11.15M | 7.64M | 9.09M |
| Operating Income | -20.21M | -14.10M | -11.15M | -7.64M | -9.09M |
| Income Before Tax | -23.08M | -17.43M | 7.06M | 11.00M | 22.87M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -23.08 | -17.43 | 7.06 | 11.00 | 22.87 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.08M | -17.43M | 7.06M | 11.00M | 22.87M |
| EBIT | -20.21M | -14.10M | -11.15M | -7.64M | -9.09M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -3.03 | -3.83 | -2.42 | -1.73 | -0.65 |
| Normalized Basic EPS | -1.92 | -2.35 | -2.31 | -1.94 | -0.64 |
| EPS Diluted | -3.03 | -3.83 | -2.42 | -1.73 | -0.66 |
| Normalized Diluted EPS | -1.92 | -2.35 | -2.31 | -1.94 | -0.66 |
| Average Basic Shares Outstanding | 33.47M | 24.22M | 18.93M | 18.93M | 18.93M |
| Average Diluted Shares Outstanding | 33.47M | 24.22M | 18.93M | 18.93M | 19.05M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |